What is the consequence of using ACE inhibitors in pregnant women?

The consequence of using ACE inhibitors in pregnant women is specifically linked to renal complications in the developing fetus. ACE inhibitors are associated with a condition known as renal tubular dysplasia, which can lead to renal tubular aplasia. This means that the developing fetus may experience serious renal issues, which can result in oligohydramnios (low amniotic fluid), lung hypoplasia (underdeveloped lungs), and skeletal deformations due to the lack of adequate amniotic fluid.

The use of ACE inhibitors during pregnancy poses significant risks, particularly during the second and third trimesters, as the fetal renal system is maturing and becoming functional. It is crucial for healthcare providers to avoid prescribing these medications to pregnant patients due to the risk of severe developmental abnormalities in the fetus.

As for the other options, excessive fetal movement is not a recognized consequence of ACE inhibitor use, increased maternal weight gain doesn't directly relate to the action of ACE inhibitors, and enhanced fetal viability contradicts the known risks associated with these medications. Thus, the focus remains on the critical risks related to fetal renal development when ACE inhibitors are used during pregnancy.